Cargando…

Antigenic responses are hallmarks of fibrotic interstitial lung diseases independent of underlying etiologies

Interstitial lung diseases (ILD) are heterogeneous conditions that may lead to progressive fibrosis and death of affected individuals. Despite diversity in clinical manifestations, enlargement of lung-associated lymph nodes (LLN) in fibrotic ILD patients predicts worse survival. Herein, we revealed...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Young me, Velez, Tania E., Upadhyay, Vaibhav, Vazquez, Sara E., Lee, Cathryn T., Selvan, Kavitha C., Law, Christopher S., Blaine, Kelly M., Hollinger, Maile K., Decker, Donna C., Clark, Marcus R., Strek, Mary E., Guzy, Robert D., Adegunsoye, Ayodeji, Noth, Imre, Wolters, Paul J., Anderson, Mark, DeRisi, Joseph L., Shum, Anthony K., Sperling, Anne I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197719/
https://www.ncbi.nlm.nih.gov/pubmed/37214861
http://dx.doi.org/10.1101/2023.05.08.23289640
Descripción
Sumario:Interstitial lung diseases (ILD) are heterogeneous conditions that may lead to progressive fibrosis and death of affected individuals. Despite diversity in clinical manifestations, enlargement of lung-associated lymph nodes (LLN) in fibrotic ILD patients predicts worse survival. Herein, we revealed a common adaptive immune landscape in LLNs of all ILD patients, characterized by highly activated germinal centers and antigen-activated T cells including regulatory T cells (Tregs). In support of these findings, we identified serum reactivity to 17 candidate auto-antigens in ILD patients through a proteome-wide screening using phage immunoprecipitation sequencing. Autoantibody responses to actin binding LIM protein 1 (ABLIM1), a protein highly expressed in aberrant basaloid cells of fibrotic lungs, were correlated with LLN frequencies of T follicular helper cells and Tregs in ILD patients. Together, we demonstrate that end-stage ILD patients have converging immune mechanisms, in part driven by antigen-specific immune responses, which may contribute to disease progression.